JP2025016545A5 - - Google Patents

Info

Publication number
JP2025016545A5
JP2025016545A5 JP2024186222A JP2024186222A JP2025016545A5 JP 2025016545 A5 JP2025016545 A5 JP 2025016545A5 JP 2024186222 A JP2024186222 A JP 2024186222A JP 2024186222 A JP2024186222 A JP 2024186222A JP 2025016545 A5 JP2025016545 A5 JP 2025016545A5
Authority
JP
Japan
Prior art keywords
antibody
linker
payload conjugate
payload
heavy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024186222A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025016545A (ja
Filing date
Publication date
Priority claimed from JP2022504337A external-priority patent/JP7629902B2/ja
Application filed filed Critical
Publication of JP2025016545A publication Critical patent/JP2025016545A/ja
Publication of JP2025016545A5 publication Critical patent/JP2025016545A5/ja
Pending legal-status Critical Current

Links

JP2024186222A 2019-03-19 2024-10-22 グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 Pending JP2025016545A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19163810 2019-03-19
EP19163810.5 2019-03-19
JP2022504337A JP7629902B2 (ja) 2019-03-19 2020-03-19 グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法
PCT/EP2020/057697 WO2020188061A1 (en) 2019-03-19 2020-03-19 Transglutaminase conjugation method with a glycine based linker

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022504337A Division JP7629902B2 (ja) 2019-03-19 2020-03-19 グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法

Publications (2)

Publication Number Publication Date
JP2025016545A JP2025016545A (ja) 2025-02-04
JP2025016545A5 true JP2025016545A5 (cg-RX-API-DMAC7.html) 2025-10-21

Family

ID=65903991

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504337A Active JP7629902B2 (ja) 2019-03-19 2020-03-19 グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法
JP2024186222A Pending JP2025016545A (ja) 2019-03-19 2024-10-22 グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022504337A Active JP7629902B2 (ja) 2019-03-19 2020-03-19 グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法

Country Status (8)

Country Link
US (1) US20220133904A1 (cg-RX-API-DMAC7.html)
EP (1) EP3941526A1 (cg-RX-API-DMAC7.html)
JP (2) JP7629902B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220144753A (cg-RX-API-DMAC7.html)
CN (1) CN113613679A (cg-RX-API-DMAC7.html)
AU (1) AU2020243056A1 (cg-RX-API-DMAC7.html)
CA (1) CA3128571A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020188061A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018337671B2 (en) 2017-09-19 2021-03-04 Paul Scherrer Institut Transglutaminase conjugation method and linker
EP3980080A1 (en) * 2019-06-10 2022-04-13 Sutro Biopharma, Inc. Immunomodulator antibody drug conjugates and uses thereof
CN114845740B (zh) 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
US20230095053A1 (en) * 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
EP4213886A1 (en) * 2020-09-18 2023-07-26 Araris Biotech AG Transglutaminase conjugation method with amino acid-based linkers
CN116801910A (zh) * 2020-10-25 2023-09-22 阿拉里斯生物技术股份公司 生产抗体-接头偶联物的手段和方法
JP7789396B2 (ja) * 2020-10-25 2025-12-22 アラリス バイオテック アーゲー 抗体-リンカーコンジュゲートを生成するための手段および方法
JP2024501121A (ja) 2020-11-25 2024-01-11 イナート・ファルマ・ソシエテ・アノニム 癌の処置
AU2021389027A1 (en) * 2020-11-30 2023-06-29 Anbition S.R.L. Multi-specific human albumin nanoparticles decorated with antibody fragments and loaded with cytotoxics
AU2022307460A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
AU2022306788A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
WO2023281482A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Cd20-targeted il-2 and its uses
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
AU2022318483A1 (en) * 2021-07-28 2024-02-22 Merck Patent Gmbh Water soluble prodrug, conjugates and uses thereof
JP2025505835A (ja) * 2022-02-22 2025-02-28 アーデーセー セラピューティクス ソシエテ アノニム トリミングされたn-グリカンを含むfc領域でのトランスグルタミナーゼを伴うコンジュゲーション方法
KR20240150807A (ko) 2022-02-22 2024-10-16 아라리스 바이오테크 아게 2개 이상의 페이로드를 포함하는 펩티드 링커
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
EP4489862A1 (en) 2022-03-09 2025-01-15 Merck Patent GmbH Anti-ceacam5 antibodies and conjugates and uses thereof
WO2023227660A1 (en) 2022-05-25 2023-11-30 Innate Pharma Nectin-4 binding agents
CN119998325A (zh) 2022-08-08 2025-05-13 Atb治疗公司 抗CD79b的人源化抗体
CN115814111B (zh) * 2022-12-05 2025-03-28 复旦大学附属中山医院 一种近红外荧光adc免疫制剂及其制备方法与应用
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
US20240424127A1 (en) 2023-01-11 2024-12-26 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
CN116077676B (zh) * 2023-02-03 2025-09-12 南京大学 蛋白质靶向降解嵌合体及其制备方法和应用
EP4665378A2 (en) * 2023-02-14 2025-12-24 Georgia State University Research Foundation, Inc. Anti-angiogenic agent and methods of using such agent
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US20250186597A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2025192692A1 (ja) * 2024-03-14 2025-09-18 東レ株式会社 癌の治療及び/又は予防用医薬組成物
WO2026008881A1 (en) 2024-07-05 2026-01-08 Synaffix B.V. Extracellular vesicles comprising biomolecule-conjugates
WO2026013234A1 (en) 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)
WO2026024870A1 (en) * 2024-07-23 2026-01-29 Sparx Bioscience Limited Peptide linkers for construction and reducing aggregation of fusion polypeptides comprising such
WO2026069134A1 (en) 2024-09-26 2026-04-02 Bright Peak Therapeutics Ag Human therapy with il-18 immunocytokines
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6660510B2 (en) 2001-12-17 2003-12-09 Food Industry Research And Development Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2123756B1 (en) 2007-02-15 2014-06-04 Ajinomoto Co., Inc. Transglutaminase having disulfide bond introduced therein
WO2008102007A1 (en) 2007-02-22 2008-08-28 Novo Nordisk Health Care Ag Transglutaminase variants with improved specificity
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US10195289B2 (en) 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
KR20190072663A (ko) * 2014-04-25 2019-06-25 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
CA2951887A1 (en) * 2014-06-12 2015-12-17 Cspc Dophen Corporation Homogenous antibody drug conjugates via enzymatic methods
CA2971246C (en) 2014-12-19 2020-07-14 F. Hoffmann-La Roche Ag Identification of transglutaminase substrates and uses therefor
ES2871624T3 (es) 2014-12-19 2021-10-29 Hoffmann La Roche Transglutaminasas microbianas, sustratos para las mismas y procedimientos para el uso de las mismas
US20180028682A1 (en) * 2015-02-09 2018-02-01 Nbe Therapeutics Ag Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
ES2736106T3 (es) 2015-03-10 2019-12-26 Bristol Myers Squibb Co Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos
WO2017025179A1 (en) 2015-08-07 2017-02-16 Merck Patent Gmbh A transglutamine tag for efficient site-specific bioconjugation
KR20230008269A (ko) * 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체

Similar Documents

Publication Publication Date Title
JP2022525704A5 (cg-RX-API-DMAC7.html)
US20200289661A1 (en) Cd48 antibodies and conjugates thereof
JP7239558B2 (ja) テトラマレイミドリンカー及びその使用
JP7815223B2 (ja) 可溶性タグを有する分子および関連方法
JP2020534030A5 (cg-RX-API-DMAC7.html)
EP3695852A1 (en) Anti-mesothelin antibody and antibody-drug conjugate thereof
PL172837B1 (pl) Preparat farmaceutyczny zawierajacy koniugaty tioeterowe PL PL PL PL PL
CN110240654A (zh) 结合cd73的抗体-药物偶联物
KR20230008723A (ko) 전하 변이체 링커
JP2018523471A5 (cg-RX-API-DMAC7.html)
US20190298846A1 (en) Cell targeting conjugates
JP2020510656A5 (cg-RX-API-DMAC7.html)
JP2023546493A5 (cg-RX-API-DMAC7.html)
JP2023529640A (ja) 治療用コンジュゲート
JP2023522392A (ja) 抗ceacam5抗体コンジュゲートおよびフォルフィリを含有する抗腫瘍組み合わせ
JP2024539989A5 (cg-RX-API-DMAC7.html)
JP2023522396A (ja) 抗ceacam5抗体コンジュゲート、トリフルリジン、およびチピラシルを含有する抗腫瘍組み合わせ
JP2023542910A5 (cg-RX-API-DMAC7.html)
JP2024542095A5 (cg-RX-API-DMAC7.html)
EP3684412A1 (en) Methods of preventing methionine oxidation in immunoconjugates
NZ779213B2 (en) Transglutaminase conjugation method with a glycine based linker
NZ779213A (en) Transglutaminase conjugation method with a glycine based linker
CN101277716A (zh) 治疗癌症的抗体
WO2025003392A1 (en) Bioconjugation systems and uses thereof
WO2025194123A1 (en) Muc16/napi-2b antibodies and methods of use